Pfizer Clinical Trial Pipeline — 249 Active Studies

Phases, active trials: Phase 1: 43, Phase 2: 47, Phase 3: 86, Other: 73

Pfizer's clinical pipeline spans oncology, rare disease, infectious disease, and inflammation. In oncology, Ibrance (palbociclib) remains a mainstay of HR+ breast cancer treatment with ongoing combination trials, while Lorbrena (lorlatinib) anchors the ALK-positive NSCLC franchise. The 2023 acquisition of Seagen brought Padcev (enfortumab vedotin) and Tukysa (tucatinib) — expanding Pfizer's ADC and HER2 capabilities significantly. In rare disease, Pfizer's hemophilia gene therapy program and pipeline in Pompe disease and Duchenne MD represent major development investments. Their mRNA platform, validated by the COVID vaccine, is being applied to influenza, RSV, and oncology vaccine targets.

• Oncology (breast, NSCLC, urothelial, hematology)
• Rare disease / gene therapy
• Inflammation / immunology
• Infectious disease / vaccines
• mRNA therapeutics

• Ibrance (palbociclib) — CDK4/6 inhibitor, HR+ breast cancer
• Lorbrena (lorlatinib) — ALK-positive NSCLC
• Padcev (enfortumab vedotin) — urothelial ADC
• Tukysa (tucatinib) — HER2+ breast/gastric/CRC
• Xtandi (enzalutamide) — prostate cancer
• Braftovi (encorafenib) — BRAF-mutant tumors

Pfizer's Seagen acquisition pipeline is actively generating new combination trials across Padcev, Tukysa, and tisotumab vedotin. Their Phase 3 program in urothelial cancer, HER2+ tumors, and cervical cancer is one of the fastest-growing competitive spaces in oncology.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Pfizer's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Pfizer may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.